ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies.
Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse.
Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geographic expansion, and momentum across all three product categories.
This momentum has continued in 2026, with net sales increasing by 24.6% year-on-year at constant currency in the first half of the year. Based on this stronger-than-anticipated trajectory, Galderma raised its full-year 2026 net sales growth guidance to 19-21% at constant currency, from 17-20% previously, while reaffirming its Core EBITDA margin guidance of approximately 26% at constant currency in a year of significant margin expansion.
Galderma today has a broad shareholder base, with L'Oréal Group holding 20% of the company’s shares and 80% of its shares in free float, further strengthening Galderma’s position in public markets.
|
“Joining the Swiss Market Index marks another milestone in Galderma’s evolution as a public company and reflects the strong momentum we have built since our IPO. Our inclusion in the SMI is recognition of the confidence investors have in our strategy and future growth prospects. With significant opportunities ahead, we remain focused on advancing our innovation pipeline, strengthening our leadership in dermatology and creating long-term value. I would like to thank our employees, healthcare professional partners and shareholders for their continued trust and support.”
FLEMMING ØRNSKOV, M.D., MPH |
